TrialAnnals of the rheumatic diseases2011

Baseline tumour necrosis factor alpha levels predict the necessity for dose escalation of infliximab therapy in patients with rheumatoid arthritis.

Tsutomu Takeuchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.